Full Text
RWD61 CHARACTERISING THE LATENCY PERIOD OF SECONDARY PRIMARY MALIGNANCY AND LYMPHOMA ONSET FOLLOWING TISAGENLECLEUCEL (CAR-T CELL THERAPY): A REAL-WORLD DATA ANALYSIS

Abstract

Authors

Roaa M. Alamri aliah aldahash

Back to Volume 49, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×